Our findings highlight that modulation of MBOAT7 may provide therapeutic benefit for suppressing inflammation in human diseases associated with dysregulation of the TLR signalling cascade, including in COVID-19 and MAFLD. Here, MBOAT7 is linked to COVID-19.